Back to Search
Start Over
Repression of transforming growth factor-beta receptor type I promoter expression by Sp1 deficiency.
- Source :
-
Oncogene [Oncogene] 2000 Sep 21; Vol. 19 (40), pp. 4660-7. - Publication Year :
- 2000
-
Abstract
- In this report, we describe the mechanism of TGF-beta receptor type I (RI) repression in the GEO human colon carcinoma cells. Treatment of GEO cells with the DNA methyltransferase inhibitor, 5 azacytidine induced RI expression and restored TGF-beta response. A stably transfected RI promoter-reporter construct (RI-Luc) expressed higher activity in the 5 aza C treated GEO cells, suggesting the activation of a transactivator for RI transcription. Gel shift analysis indicated enhanced binding of proteins from the 5 aza C treated nuclear extracts to radiolabeled Sp1 oligonucleotides specifically contained in the RI promoter. Protein stability studies after cyclohexamide treatment suggested an increase in the Sp1 protein stability from the 5 aza C treated GEO cells. Further, transfection of Sp1 cDNA into untreated GEO control cells increased RI promoter activity and thus induced RI expression. 5 aza C mediated Sp1 expression in Sp1 deficient GEO colon and MCF-7 breast cancer cells also enhanced the activity of several other Sp1 dependent promoters such as TGF-beta receptor type II (RII), Cyclin A and p21/waf1/cip1. These results indicate that restoration of Sp1 in several different types of Sp1 deficient cells leads to enhanced activation of a wide range of Sp1 dependent promoters.
- Subjects :
- Adenocarcinoma genetics
Adenocarcinoma metabolism
Adenocarcinoma pathology
Antimetabolites, Antineoplastic pharmacology
Azacitidine pharmacology
Breast Neoplasms genetics
Breast Neoplasms metabolism
Breast Neoplasms pathology
Colonic Neoplasms genetics
Colonic Neoplasms metabolism
Colonic Neoplasms pathology
Cyclin A biosynthesis
Cyclin A genetics
Cyclin-Dependent Kinase Inhibitor p21
Cyclins biosynthesis
Cyclins genetics
DNA (Cytosine-5-)-Methyltransferases antagonists & inhibitors
DNA Methylation drug effects
Enzyme Inhibitors pharmacology
Female
Humans
Neoplasm Proteins biosynthesis
Neoplasm Proteins deficiency
Protein Serine-Threonine Kinases biosynthesis
Receptor, Transforming Growth Factor-beta Type I
Receptor, Transforming Growth Factor-beta Type II
Receptors, Transforming Growth Factor beta biosynthesis
Recombinant Fusion Proteins physiology
Sp1 Transcription Factor physiology
Transcriptional Activation
Transfection
Tumor Cells, Cultured drug effects
Tumor Cells, Cultured metabolism
Activin Receptors, Type I
Gene Expression Regulation, Neoplastic drug effects
Neoplasm Proteins genetics
Neoplasm Proteins physiology
Promoter Regions, Genetic genetics
Protein Serine-Threonine Kinases genetics
Receptors, Transforming Growth Factor beta genetics
Sp1 Transcription Factor deficiency
Subjects
Details
- Language :
- English
- ISSN :
- 0950-9232
- Volume :
- 19
- Issue :
- 40
- Database :
- MEDLINE
- Journal :
- Oncogene
- Publication Type :
- Academic Journal
- Accession number :
- 11030155
- Full Text :
- https://doi.org/10.1038/sj.onc.1203822